Key Drivers
- Large cash buffer
- Negative margins
- High cash burn
AIAI Summary
Relay is now an event‑driven biotech where zovegalisib's Phase 3 readout and Breakthrough status will largely drive valuation over the next 12–24 months, so investors should monitor the pivotal data timing, cash runway (~$555M vs ~$235M annual burn) and any partnership discussions as near‑term trigger points while preparing for rapid downside if Phase 3 disappoints or dilutive financing becomes necessary.
Price Chart
Financial Metrics
Deep Analysis
Research tool. Not personalized advice.
Fundamental Analysis
Key Financial Insights:
- •Large cash buffer
- •Negative margins
- •High cash burn
RLAY combines a very strong balance sheet (large cash/investments, minimal leverage) with severe operating losses and negative cash flow that risk depleting its cash buffer if high R&D/opex and negligible revenue persist.
Price Behavior
Key Price Behavior Insights:
- •Modest uptrend
- •Buyer support
- •Elevated volatility
RLAY is showing a modest short-term uptrend (last month SMA ≈ $9.88) after a ~14% rise from $8.70 to $9.91, with buyers defending the low‑$9s and upside toward $10.80 but elevated intraperiod volatility (~24% range) that raises both opportunity and risk.
~24% intraperiod trading range between $8.70 and $10.80 indicating elevated short-term volatility
Sentiment & News
Key News Insights:
- •Breakthrough designation
- •11.1-month PFS
- •Institutional buying
Relay Therapeutics' zovegalisib delivered an 11.1‑month median PFS in heavily pretreated PI3Kα‑mutant HR+/HER2‑ MBC, earned FDA Breakthrough designation, and the company showed stronger-than-expected financials, growing institutional support and positive stock momentum.
The combined clinical, regulatory and financial momentum should boost RLAY's probability of success and underpin further upside into the Phase 3 ReDiscover-2 catalyst
Similar Companies in Healthcare
Other companies in the same sector with AI ratings